Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

Braulke, Friederike; Schulz, Xenia; Germing, Ulrich; Schuler, Esther; Platzbecker, Uwe; Nolte, Florian; Hofmann, Wolf‐Karsten; Giagounidis, Aristoteles; Götze, Katharina; Lübbert, Michael; Schlenk, Richard F.; Schanz, Julie; Bacher, Ulrike; Ganser, Arnold; Büsche, Guntram; Letsch, Anne; Schafhausen, Philippe; Bug, Gesine; Brümmendorf, Tim H.; Haas, Rainer; Trümper, Lorenz; Shirneshan, Katayoon; Haase, Detlef

doi:10.1007/s00277-017-2983-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

To the Editor1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2024

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, we found that discrepancies in CNV detection can be accounted to more sensitive detection of abnormalities in CBA due to a proliferative advantage of the abnormal clone and due to smaller clone sizes in PB compared to BM supported by mutational analysis. In cases with large differences in clone size between BM and PB CD34-enriched PB samples might help to overcome these limitations [ 6 – 8 ].

Fig.…”

Section: To the Editormentioning

confidence: 99%